Plevová P, Bouchal J, Fiurásková M, Foretová L, Navrátilová M, Zapletalová J, Curík R, Kubala O, Prokop J, Kolár Z
Institute of Pathology and Laboratory of Molecular Pathology, Medical Faculty of the Palacký University, Olomouc, Czech Republic.
Neoplasma. 2007;54(4):263-8.
The PML protein is concentrated in the PML nuclear bodies. Downregulation of the PML protein has been described in various types of cancer and is in accordance with the fact that dysqualification of tumor suppressive functions of the PML protein might promote cancer development. Various differences have been described between sporadic breast cancer and that associated with BRCA1 and BRCA2 gene mutations. Expression of the PML protein has not been studied yet. The aim of this study was to determine if there is any difference in PML protein expression in breast cancer of BRCA1 and BRCA2 gene mutation carriers compared to sporadic breast cancer and if the PML protein can be used as a prognostic marker. There were 47 breast cancer samples included, 14 and 10 from BRCA1 and BRCA2 germline mutation carriers, respectively, and 23 from patients without a BRCA1/BRCA2 germline mutation. Immunofluorescence staining was used. Downregulation of PML protein expression was found in 2 of 14 (14%), 3 of 10 (30%) and 15 of 47 (31%) cases of breast cancer samples from BRCA1, BRCA2 and no BRCA1/BRCA2 mutation carriers, respectively (p(BRCA1) = 0.019; p(BRCA2) = 0.111). There was no correlation between PML protein expression and age, histological types, estrogen and progesterone receptor, c-erbB-2 and PCNA expression, TNM classification, disease-free and overall survival. In conclusion, the PML protein is downregulated in approximately 30% of breast cancers cases. Downregulation of PML protein expression was significantly less frequent in BRCA1 mutation carriers compared to sporadic cases. No correlation was found between PML protein expression and any of the other clinical and laboratory characteristics.
PML蛋白集中在PML核体中。在各种类型的癌症中均已发现PML蛋白表达下调，这与PML蛋白的肿瘤抑制功能丧失可能促进癌症发展这一事实相符。散发性乳腺癌与与BRCA1和BRCA2基因突变相关的乳腺癌之间存在多种差异。目前尚未对PML蛋白的表达进行研究。本研究的目的是确定与散发性乳腺癌相比，BRCA1和BRCA2基因突变携带者的乳腺癌中PML蛋白表达是否存在差异，以及PML蛋白是否可作为预后标志物。共纳入47例乳腺癌样本，其中分别有14例和10例来自BRCA1和BRCA2种系突变携带者，23例来自无BRCA1/BRCA2种系突变的患者。采用免疫荧光染色法。在来自BRCA1、BRCA2和无BRCA1/BRCA2突变携带者的乳腺癌样本中，PML蛋白表达下调的病例分别为14例中的2例（14%）、10例中的3例（30%）和47例中的15例（31%）（p(BRCA1)=0.019；p(BRCA2)=0.111）。PML蛋白表达与年龄、组织学类型、雌激素和孕激素受体、c-erbB-2和PCNA表达、TNM分期、无病生存期和总生存期之间均无相关性。总之，约30%的乳腺癌病例中PML蛋白表达下调。与散发病例相比，BRCA1突变携带者中PML蛋白表达下调的频率明显较低。未发现PML蛋白表达与任何其他临床和实验室特征之间存在相关性。
